• Framingham Risk Score Sheet
• Framingham Score Risk Calculator
• Framingham Risk Score Calculator Pdf Viewer 2017

In the text below the calculator you can read more about the scoring method and result interpretation. The Framingham risk score calculator is based on a series of known cardiovascular risk factors that can indicate the 10-year risk of a patient to develop heart disease, especially coronary heart disease. The Framingham Risk Score remained below 10% for all deciles of CHA-predicted risk in the 18 to 29 year old cohort. Framingham-predicted risk reached 12% only in the 30 to 39 year old cohort in the highest decile of CHA-predicted risk, despite substantial risk factor burden. This GRACE risk score calculator estimates mortality risk within 6 months to 3 years of myocardial infarction in patients with acute coronary syndrome.

Contents.Cardiovascular Risk Scoring systems The Framingham Risk Score is one of a number of scoring systems used to determine an individual's chances of developing cardiovascular disease. A number of these scoring systems are available online. Cardiovascular risk scoring systems give an estimate of the probability that a person will develop cardiovascular disease within a specified amount of time, usually 10 to 30 years.Because they give an indication of the risk of developing cardiovascular disease, they also indicate who is most likely to benefit from prevention. For this reason, cardiovascular risk scores are used to determine who should be offered preventive drugs such as drugs to lower blood pressure and drugs to lower cholesterol levels.For example, nearly 30% of coronary heart disease (CHD) events in both men and women were singularly attributable to blood pressure levels that exceeded high normal (≥130/85), showing that blood pressure management and monitoring is paramount both to cardiovascular health and prediction of outcomes. Usefulness Because risk scores such as the Framingham Risk Score give an indication of the likely benefits of prevention, they are useful for both the individual patient and for the clinician in helping decide whether lifestyle modification and preventive medical treatment, and for patient education, by identifying men and women at increased risk for future cardiovascular events.(CHD) risk at 10 years in percent can be calculated with the help of the Framingham Risk Score.

Individuals with low risk have 10% or less CHD risk at 10 years, with intermediate risk 10-20%, and with high risk 20% or more. However it should be remembered that these categorisations are arbitrary.A more useful metric is to consider the effects of treatment. This section does not any. Unsourced material may be challenged. ( September 2019) Some patients without known CHD have risk of cardiovascular events that is comparable to that of patients with established CHD.

Cardiology professionals refer to such patients as having a CHD risk equivalent. These patients should be managed as patients with known CHD.CHD risk equivalents are patients with a 10-year risk for or 20%. CHD risk equivalents are primarily other clinical forms of atherosclerotic disease. The NCEP's ATP III guidelines also list diabetes as a CHD risk equivalent since it also has a 10-year risk for CHD around 20%. NCEP ATP III CHD risk equivalents are:. clinical (CHD). symptomatic (CAD).

(PAD). (AAA).Analysis of the US population with the Framingham/ATP III criteria The Framingham/ATP III criteria were used to estimate CHD risk in the USA.

Data from 11,611 patients from a very large study, the III, were used. The patients were 20 to 79 years of age, and had no self reported CHD, stroke, peripheral arterial disease, or diabetes.The results: 82% of patients had low risk (10% or less CHD risk at 10 years). 16% had intermediate risk (10-20%). 3% had high risk (20% or more).High risk was most commonly found in patients with advanced age, and was more common in men than women. Scoring Framingham Risk Score for Women Age: 20–34 years: Minus 7 points. 35–39 years: Minus 3 points. 40–44 years: 0 points.

45–49 years: 3 points. 50–54 years: 6 points.

55–59 years: 8 points. 60–64 years: 10 points.

65–69 years: 12 points. 70–74 years: 14 points. 75–79 years: 16 points.Total cholesterol, mg/dL: Age 20–39 years: Under 160: 0 points. 160-199: 4 points.

200-239: 8 points. 240-279: 11 points. 280 or higher: 13 points.

Age 40–49 years: Under 160: 0 points. 160-199: 3 points. 200-239: 6 points. 240-279: 8 points. 280 or higher: 10 points.

Age 50–59 years: Under 160: 0 points. 160-199: 2 points. 200-239: 4 points. 240-279: 5 points. 280 or higher: 7 points.

Age 60–69 years: Under 160: 0 points. 160-199: 1 point.

200-239: 2 points. 240-279: 3 points. 280 or higher: 4 points. Age 70–79 years: Under 160: 0 points. 160-199: 1 point. 200-239: 1 point. 240-279: 2 points.

280 or higher: 2 points.If cigarette smoker: Age 20–39 years: 9 points. Age 40–49 years: 7 points. Age 50–59 years: 4 points. Age 60–69 years: 2 points.

Age 70–79 years: 1 point.All non smokers: 0 points.HDL cholesterol, mg/dL: 60 or higher: Minus 1 point. 50-59: 0 points. 40-49: 1 point.

Under 40: 2 points.Systolic blood pressure, mm Hg: Untreated: Under 120: 0 points. 120-129: 1 point. 130-139: 2 points.

140-159: 3 points. 160 or higher: 4 points. Treated: Under 120: 0 points. 120-129: 3 points.

130-139: 4 points. 140-159: 5 points. 160 or higher: 6 points.10-year risk in%: Points total: Under 9 points: 25= Over 30%Framingham Risk Score for Men Age: 20–34 years: Minus 9 points. 35–39 years: Minus 4 points. 40–44 years: 0 points. 45–49 years: 3 points.

50–54 years: 6 points. 55–59 years: 8 points. 60–64 years: 10 points. 65–69 years: 11 points. 70–74 years: 12 points. 75–79 years: 13 points.Total cholesterol, mg/dL: Age 20–39 years: Under 160: 0 points. 160-199: 4 points.

200-239: 7 points. 240-279: 9 points. 280 or higher: 11 points.

Age 40–49 years: Under 160: 0 points. 160-199: 3 points. 200-239: 5 points. 240-279: 6 points. 280 or higher: 8 points.

Age 50–59 years: Under 160: 0 points. 160-199: 2 points.

200-239: 3 points. 240-279: 4 points. 280 or higher: 5 points. Age 60–69 years: Under 160: 0 points. 160-199: 1 point. 200-239: 1 point.

240-279: 2 points. 280 or higher: 3 points. Age 70–79 years: Under 160: 0 points. 160-199: 0 points.

200-239: 0 points. 240-279: 1 point.

280 or higher: 1 point.If cigarette smoker: Age 20–39 years: 8 points. Age 40–49 years: 5 points. Age 50–59 years: 3 points. Age 60–69 years: 1 point. Age 70–79 years: 1 point.All non smokers: 0 points.HDL cholesterol, mg/dL: 60 or higher: Minus 1 point. 50-59: 0 points. 40-49: 1 point.

Under 40: 2 points.Systolic blood pressure, mm Hg: Untreated: Under 120: 0 points. 120-129: 0 points. 130-139: 1 point. 140-159: 1 point. 160 or higher: 2 points.

Treated: Under 120: 0 points. 120-129: 1 point. 130-139: 2 points. 140-159: 2 points. 160 or higher: 3 points.10-year risk in%:Points total:0 point. ^ Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (May 1998).

'Prediction of coronary heart disease using risk factor categories'. 97 (18): 1837–47. ^ D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB (22 January 2008). 'General cardiovascular risk profile for use in primary care: the Framingham Heart Study'. 117 (6): 743–53.

Framingham Risk Score Sheet

Collins, Dylan; Lee, Joseph; Bobrovitz, Niklas; Koshiaris, Constantinos; Ward, Alison; Heneghan, Carl (2016-10-14). 'Simple and adaptable R implementation of WHO/ISH cardiovascular risk charts for all epidemiological subregions of the world'. Retrieved 2013-09-14. Framingham Heart Study. Retrieved 7 May 2013.

Estimation of cardiovascular risk in an individual patient without known cardiovascular disease. In: UpToDate Textbook of Medicine. Basow, DS (Ed). Massachusetts Medical Society, and Wolters Kluwer publishers, The Netherlands.

2010. Collins, Dylan Raymond James; Tompson, Alice; Onakpoya, Igho; Roberts, Nia; Ward, Alison; Heneghan, Carl (2017). 7 (3): e013650.

D'Agostino RB, Grundy S, Sullivan LM, Wilson P (July 2001). 'Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation'. 286 (2): 180–7. Tzoulaki, I.; Liberopoulos, G.; Ioannidis, JP.

'Assessment of claims of improved prediction beyond the Framingham risk score'. 302 (21): 2345–52.

Framingham Score Risk Calculator

Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, Ebrahim S (Nov 2003). 327 (7426): 1267. Liu J; Hong Y; D'Agostino RB Sr; Wu Z; Wang W; Sun J; Wilson PW; Kannel WB; Zhao D (Jun 2004). 'Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study'. 291 (21): 2591–9.

Sacco RL, Khatri M, Rundek T, Xu Q, Gardener H, Boden-Albala B, Di Tullio MR, Homma S, Elkind MS, Paik MC (Dec 2009). J Am Coll Cardiol. 54 (24): 2303–11.

Conroy R (2003). 'Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project'. European Heart Journal. 24 (11): 987–1003. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM (Jun 2003). 'Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project'. 24 (11): 987–1003.

^ 'Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report'. 106 (25): 3143–421. December 2002. Ford ES, Giles WH, Mokdad AH (May 2004). 'The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III'.

43 (10): 1791–6. Retrieved 2013-09-14. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ (February 2009). 373 (9665): 739–45. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ (August 2004).

Framingham Risk Score Calculator Pdf Viewer 2017

'Lifetime risk for development of atrial fibrillation: the Framingham Heart Study'. 110 (9): 1042–6.